CAS: 25779-13-9; (S)-1-Phenylethane-1,2-Diol

上下游产品

CAS号582-24-1 2-羟基苯乙酮 | CAS号21210-43-5 (S)-(+)-扁桃酸甲酯 | CAS号292638-84-7 phenylene-ethylene | CAS号1074-12-0 苯基丙醇水合物 | CAS号17199-29-0 (S)-(+)-扁桃酸 | CAS号96-09-3 氧化苯乙烯 | CAS号93-56-1 (±)-1-苯基-1,2-乙二醇 | CAS号70-11-1 2-溴苯乙酮 | CAS号103548-09-0 (S)-2-((tert-bu... | CAS号147441-62-1 (4S)-2,2-dimeth... | CAS号40435-14-1 (S)-(+)-1-苯基-1,... | CAS号582-24-1 2-羟基苯乙酮 | CAS号93-56-1 (±)-1-苯基-1,2-乙二醇 | CAS号1517-69-7 (R)-(+)-1-苯基乙醇 | CAS号20780-54-5 (S)-环氧苯乙烷 | CAS号20780-53-4 (R)-环氧苯乙烷 | CAS号16355-00-3 (R)-(-)-1-苯基-1,2-乙二醇 | CAS号26164-26-1 (S)-(+)-α-甲氧基苯乙酸 | CAS号56613-80-0 D-苯甘氨醇

苯乙烯置于a-无水葡萄糖酯,Escherichia Coli (Ssp1)体系中,用 正十六烷 用作溶剂,化学反应 8.0H,以92%的收率获得(S)-(+)-1-苯基-1,2-乙二醇
参考文献:芳基烯烃的对映选择性的反式-二羟基化由生物催化级联用重组大肠杆菌共表达单加氧酶和环氧化物水解酶
标题:芳基烯烃的对映选择性的反式-二羟基化由生物催化级联用重组大肠杆菌共表达单加氧酶和环氧化物水解酶
摘要:通过细胞内环氧化和水解的级联生物催化被开发为一种绿色高效的方法,用于芳基烯烃的对映选择性二羟基化,以高ee和高收率制备手性邻位二醇.共表达苯乙烯单加氧酶(smo)和环氧化物水解酶speh的大肠杆菌(ssp1)是一种简单有效的生物催化剂,用于末端芳基烯烃1A-15A的s-对映选择性二羟基化,得到(S)-邻位二醇1C-15C高ee(10二醇为97.5-98.6%; 3二醇为92.2-93.9%)和高收率(6二醇为91-99%; 2二醇为86-88%; 3二醇为67%).将smo和环氧化物水解酶steh组合起来对speh作为级联生物催化的生物催化剂具有互补的区域选择性,从而产生芳基烯烃的r-对映选择性二羟基化反应,这是这种方法逆转了级联生物催化整体对映选择性的第一个例子.共表达smo和steh的大肠杆菌(sst1)也被设计为绿色和高效的生物催化剂,用于末端芳基烯烃1A-15A的r-二羟基化,得到(R)-邻二醇1C
Doi:10.1021/cs400992Z

专利信息

专利号:US-10337033-B2
优先权日:2016-12-30
标 题 :Carbonyl reductase oligomers and their application in synthesis of chiral alcohols
发明人：ZHANG RONGZHEN; XU YAN; LI KUNPENG
权利人:ZHANG RONGZHEN; XU YAN; LI KUNPENG; UNIV JIANGNAN
摘要:Disclosed are methods for the synthesis of chiral alcohols by Sortase A-mediated oxidoreductase oligomers, which relates to the field of biocatalysis. In the present disclosure, oxidoreductase oligomers were used as biocatalysts for chiral alcohol preparation. Compared to wild-type enzymes, the oxidoreductase oligomers significantly improved catalytic activity and thermal stability. The sortase A-mediated oxidoreductase oligomers had 6-8 folds improvement in specific activity over that of the wild-type enzymes. The oligomers displayed a T m value 6-12° C. higher than that of the wild-type, suggesting the sortase A-mediated oxidoreductase oligomers significantly improved thermostability of the enzymes. The oxidoreductase oligomers catalyzed asymmetric transformation to produce (S)-1-phenyl-1,2-ethanediol or (R)-1-phenethyl alcohol within 3-6 hr, with an optical purity of 98%-100% and a yield of 98%-99%.

专利号:US-6630602-B1
优先权日:1998-04-16
标题 :Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, a method for their synthesis and pharmaceutical compositions containing them
发明人：BIALER MEIR; SPIGELSTEIN OFER; YAGEN BORIS
权利人:YISSUM RES DEV CO
摘要:The present invention relates to racemic propylisopropyl acetic acid and propylisopropyl acetamide and their isomers in their racemic and stereospecific forms, for use in treatment of neurological and psychotic disorders, and affective disorders and to treat pain, headaches and migraines. The isomers are of the compound formula I:wherein R1 is a methyl or ethyl group; R2 is H, methyl or an ethyl group; R3 is ethyl or a propyl group; and R4 is a hydroxyl or amide group; and the total number of carbon atoms in said compound is 8, provided that when R1 is a methyl group and R4 is an amide group, R2 and R3 are not ethyl, further provided that when R1 is an ethyl and R4 a hydroxyl group, only stereoisomers of the compound are referred to. The present invention further relates to a method for the stereoselective synthesis of the 2S and 2R stereoisomer of PID and PIA. The present invention also relates to pharmaceutical compositions containing as an active ingredient a racemic mixture or stereoisomers of the compounds of the general formula (I), which are useful for the treatment of neurological and psychotic disorders, and affective disorders and to treat pain, headaches and migraines.

专利号:US-6969732-B2
优先权日:1999-04-12
标 题 :Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, a method for their synthesis and pharmaceutical compositions containing them
发明人：BIALER MEIR; SPIGELSTEIN OFER; YAGEN BORIS
权利人:YISSUM RES DEV CO
摘要:The present invention relates to racemic propylisopropyl acetic acid and propylisopropyl acetamide and their isomers in their racemic and stereospecific forms, for use in treatment of neurological and psychotic disorders, and affective disorders and to treat pain, headaches and migraines. The isomers are of the compound formula I n n R 1 is a methyl or ethyl group; R 2 is H, methyl or an ethyl group; R 3 is ethyl or a propyl group; and R 4 is a hydroxyl or amide group,n nand the total number of carbon atoms in said compound is 8, provided that when R1 is a methyl group and R4 is an amide group, R2 and R3 are not ethyl, further provided that when R1 is an ethyl and R4 a hydroxyl group, only stereoisomers of the compound are referred to.n nn The present invention further relates to a method for the stereoselective synthesis of the 2R stereoisomer of PID and PIA. The present invention also relates to pharmaceutical compositions containing as an active ingredient a racemic mixture or stereoisomers of the compounds of the general formula (I), which are useful for the treatment of neurological and psychotic disorders, and affective disorders and to treat pain, headaches and migraines.

专利号:US-6838581-B2
优先权日:2002-12-04
标题:Process for the preparation of enantiomerically pure 3-phenyl-3-hydroxypropylamine
发明人：KUMAR PRADEEP; PANDEY RAJESH KUMAR
权利人:COUNCIL SCIENT IND RES
摘要:The present invention relates to an improved process for the synthesis of enantiomerically pure 3-phenyl-3-hydroxypropylamine of formula I; more particularly the present invention relates to the said process using styrene; n n nthe synthetic strategy features a Sharpless asymmetric dihydroxylation (SAD) route to the target compound, using styrene, a readily accessible starting material gives the optically pure dihydroxy compound (ee >97%; the selective monotosylation of primary alcohol, nucleophilic displacement by cyano and subsequent reduction to amino group furnishes the desired 3-phenyl-3-hydroxypropylamine in enatiomerically pure form, a key intermediate in the synthesis of variety of oxetine related anti-depressant drugs.

专利号:US-2019276389-A1
优先权日:2015-12-18
标题:Synthesis of aryl cyclohexane ester derivatives useful as sensates in consumer products
发明人：WOS JOHN AUGUST; YELM KENNETH EDWARD; BUNKE GREGORY MARK; FREDERICK HEATH ALAN; REILLY MICHAEL; HAUGHT JOHN CHRISTIAN; SREEKRISHNA KOTI TATACHAR; LIN YAKANG
权利人:PROCTER & GAMBLE
摘要:Personal care compositions, such as oral care and skin care compositions containing a flavor/perfume system comprising one or more coolants. The pleasant cool sensation provided by a coolant is enhanced in terms of quicker onset, greater intensity, impact or longer duration, which improves appeal and acceptability of the compositions to consumers.

专利号:WO-2023091726-A1
优先权日:2021-11-18
标题:Inhibitors of cyclin‑dependent kinase 12 (cdk12)
发明人：BENOIT GUILLAUME; CARULLI JOHN; CHEN FEI; CHUAQUI CLAUDIO; CIBLAT STEPHANE; COOPER ELLIOT; DAGENAIS ROBIN; HU SHANHU; KABRO ANZHELIKA; LAPLACA DEREK; MARINEAU JASON; MOEBIUS DAVID; MOON DIANE; SOLODININ ANDREI; WHITMORE KENNETH
权利人:SYROS PHARMACEUTICALS INC
摘要:The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).